<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823654</url>
  </required_header>
  <id_info>
    <org_study_id>08-156</org_study_id>
    <nct_id>NCT00823654</nct_id>
  </id_info>
  <brief_title>Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations</brief_title>
  <official_title>Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer BRCA Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how the cancer treatment affects the ovaries. Cancer&#xD;
      treatment can make it hard for a person to conceive a child in the future. It may also bring&#xD;
      on early menopause. We will check blood levels of hormones that the ovaries produce. We will&#xD;
      do this before, during, and after the cancer treatment. We will also ask the patient to fill&#xD;
      out questionnaires about their menstrual cycle (periods) and information about your health&#xD;
      and pregnancies. This may help us learn which women will be more likely to have early&#xD;
      menopause.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2009</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>characterize the changes in serum AMH from baseline to 1 year post-chemo (or 1 year into hormonal therapy if no chemotherapy planned)</measure>
    <time_frame>2 years</time_frame>
    <description>in premenopausal breast cancer patients &amp; to characterize the changes in serum AMH from baseline to 1 year in unaffected high risk BRCA mutation carriers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the changes in serum estradiol and FSH from baseline to one year postchemotherapy (or 1 year into hormonal therapy if no chemotherapy planned) in premenopausal breast cancer patients and BRCA mutation carriers.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the changes over time in serum AMH, estradiol, and FSH in premenopausal breast cancer patients and unaffected high risk BRCA mutation carriers.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the impact of commonly used therapies for early-stage breast cancer on self-reported monthly menstrual cycles and future pregnancy/reproductive health.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the differences in ovarian reserve between BRCA1+ and BRCA2+ women.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study sexual health and function in unaffected high risk BRCA mutation carriers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">339</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Premenopausal Women with Early Stage Breast Cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected High Risk Women with BRCA mutations</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw and questionnaires</intervention_name>
    <description>At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment&#xD;
↓&#xD;
Tests in the middle of chemotherapy (if applicable):&#xD;
Blood draw and collection of monthly menstrual calendars ↓&#xD;
Tests when chemotherapy is over (if applicable):&#xD;
Blood draw and collection of monthly menstrual calendars&#xD;
↓&#xD;
Tests every 4 months for about 1 year:&#xD;
Blood draw, collection of monthly menstrual calendars, and questionnaire ↓&#xD;
Tests every 6 months for about 1 year:&#xD;
Blood draw, collection of monthly menstrual calendars, and questionnaire&#xD;
↓&#xD;
Yearly follow-up for about 2 years:&#xD;
Blood draw collection of monthly menstrual calendars, and questionnaire</description>
    <arm_group_label>Premenopausal Women with Early Stage Breast Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw and questionnaires</intervention_name>
    <description>Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent&#xD;
↓ Register patients at Memorial Sloan-Kettering Cancer Center&#xD;
↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)&#xD;
↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires&#xD;
↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires&#xD;
↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires</description>
    <arm_group_label>Unaffected High Risk Women with BRCA mutations</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of premenopausal women with early-stage breast cancer will be recruited from the&#xD;
        Breast Cancer Service at MSKCC and New York Presbyterian Hospital-Weill Medical College of&#xD;
        Cornell University. In addition, breast cancer patients seeking consultation with a&#xD;
        reproductive endocrinologist to address issues of fertility preservation prior to the start&#xD;
        of therapy will be offered participation (Dr. Oktay at Yale Medicine.&#xD;
&#xD;
        Patients of unaffected high risk premenopausal women with BRCA mutations will be recruited&#xD;
        from the Breast Cancer Services especially the high risk surveillance clinics at MSKCC and&#xD;
        New York Presbyterian Hospital-Weill Medical College of Cornell Univeristy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Premenopausal Women with Early Stage Breast Cancer&#xD;
&#xD;
          -  Premenopausal female patients age 18-44 with breast cancer as defined as:&#xD;
&#xD;
             a. AJCC Stage 0-III breast cancer, regardless of hormone-receptor status or&#xD;
             HER2-overexpression, before the start of planned adjuvant or neoadjuvant chemotherapy&#xD;
             and/or hormonal therapy. If chemotherapy is planned, the regimen must be either CMF,&#xD;
             anthracycline containing, or taxane containing. If hormonal therapy is planned, the&#xD;
             regimen must be limited to tamoxifen. All biologics (e.g. bevacizumab, trastuzumab,&#xD;
             lapatinib, etc.) are allowed in addition to the above therapies.&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Have regular menstrual cycles; patients can have no more than 1 irregular cycle (too&#xD;
             early or too late) within the past year or were pregnant in the past 12 months, and/or&#xD;
             at least 10 spontaneous cycles within the past year.&#xD;
&#xD;
        Subject Inclusion:&#xD;
&#xD;
        For Unaffected High Risk Premenopausal Women with BRCA mutations&#xD;
&#xD;
          -  Premenopausal Women ages 25-45 with known BRCA mutations&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Have regular menstrual (21-35 days); patients can have no more than 1 irregular cycle&#xD;
             (too early or too late) within the past year and/or at least 10 spontaneous cycles&#xD;
             within the past year.&#xD;
&#xD;
          -  No history of breast or ovary cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For Cohort of Premenopausal Women with Early Stage Breast Cancer&#xD;
&#xD;
          -  Prior therapy for breast cancer or any other cancer, such as chemotherapy, hormonal&#xD;
             therapy or immunotherapy.&#xD;
&#xD;
          -  Ovarian resection, unilateral or bilateral oophorectomy, hysterectomy or radiation to&#xD;
             pelvic region.&#xD;
&#xD;
          -  Plans for risk-reducing bilateral oophorectomy within one year of completion of&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Prior known infertility; infertility is defined as one year of inability to conceive&#xD;
             despite unprotected intercourse and/or the need to use medication (e.g clomiphene) or&#xD;
             assisted reproductive technology (e.g. intrauterine insemination or in vitro&#xD;
             fertilization) to attempt pregnancy.&#xD;
&#xD;
          -  Family history of a first-degree relative with non-surgical menopause &lt; age 40&#xD;
&#xD;
          -  Current pregnancy.&#xD;
&#xD;
        Subject Exclusion Criteria:&#xD;
&#xD;
        For Unaffected High Risk Premenopausal Women with BRCA mutation&#xD;
&#xD;
          -  Prior chemotherapy or immunotherapy for breast cancer or any other cancer&#xD;
&#xD;
          -  Ovarian resection, unilateral or bilateral oophorectomy, hysterectomy or radiation to&#xD;
             pelvic region or ovarian disease (e.g. polycystic ovarian syndrome).&#xD;
&#xD;
          -  Plans for risk-reducing bilateral oophorectomy within one year&#xD;
&#xD;
          -  Prior known infertility; (except women who have undergone voluntary tubal ligation);&#xD;
             infertility is defined as one year of inability to conceive despite unprotected&#xD;
             intercourse and/or the need to use medication (e.g clomiphene) or assisted&#xD;
             reproductive technology (e.g. intrauterine insemination or in vitro fertilization) to&#xD;
             attempt pregnancy.&#xD;
&#xD;
          -  Family history of a first-degree relative with non-surgical menopause &lt; age 40&#xD;
&#xD;
          -  Current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shari Goldfarb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shari Goldfarb, MD</last_name>
    <phone>646-888-5080</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimberly Van Zee, MD</last_name>
    <phone>646-888-5362</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
    <contact_backup>
      <last_name>Kimberly Van Zee, MD</last_name>
      <phone>646-888-5362</phone>
    </contact_backup>
    <investigator>
      <last_name>Shari Goldfarb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Goldfarb, MD</last_name>
      <phone>646-888-5080</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Questionaires</keyword>
  <keyword>Blood draw</keyword>
  <keyword>BRCA1</keyword>
  <keyword>BRCA2</keyword>
  <keyword>08-156</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

